Granules India

Granules GGP plant1

Granules India Limited is a pharmaceutical manufacturing company based in Hyderabad, India. Founded in 1984, it has grown to become one of the leading firms in the pharmaceutical sector, specializing in the production of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company's focus on the production of high-volume drugs, such as Paracetamol, Ibuprofen, Metformin, and Guaifenesin, has positioned it as a key player in the global pharmaceutical supply chain.

History

Granules India was established in 1984 with a vision to provide high-quality pharmaceutical products at affordable prices. Over the years, it has expanded its operations globally, establishing manufacturing facilities and offices in several countries, including the United States, China, and several European nations. The company's commitment to quality and innovation has been instrumental in its growth and success in the competitive pharmaceutical industry.

Products and Services

Granules India's product portfolio is diverse, covering a wide range of therapeutic categories. The company's products can be broadly categorized into three main segments:

Active Pharmaceutical Ingredients (APIs)

APIs are the essential components of any drug that produce the intended effects. Granules India manufactures a variety of APIs, focusing on those with high demand and application in various therapeutic areas.

Pharmaceutical Formulation Intermediates (PFIs)

PFIs are critical in the drug development process, serving as the building blocks for finished dosage forms. Granules India provides a range of PFIs, facilitating the production of complex pharmaceutical formulations.

Finished Dosages (FDs)

The company also produces finished dosage forms, including tablets, capsules, and powders, ready for consumption by patients. These products are manufactured under strict quality control to ensure safety and efficacy.

Quality and Compliance

Granules India places a strong emphasis on quality and compliance, adhering to international regulatory standards. The company's manufacturing facilities are approved by major regulatory bodies, including the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the European Medicines Agency (EMA). This commitment to quality ensures that Granules India's products meet the highest standards of safety and efficacy.

Global Presence

With a strategic focus on expanding its global footprint, Granules India has established a significant presence in key markets around the world. The company's international operations are supported by a robust supply chain, ensuring the timely delivery of products to meet the needs of customers and patients globally.

Corporate Social Responsibility

Granules India is committed to making a positive impact on society through various corporate social responsibility (CSR) initiatives. These initiatives focus on health care, education, and community development, aiming to improve the quality of life for underprivileged communities.

Future Outlook

As Granules India continues to grow, it remains focused on innovation and expanding its product portfolio to address the evolving needs of the global pharmaceutical market. The company's ongoing investments in research and development, along with its commitment to sustainability and social responsibility, position it well for continued success in the years to come.

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia